• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Scientific reports. >Efficacy and safety of low dose alteplase for intravenous thrombolysis in Asian stroke patients: a meta-analysis
【24h】

Efficacy and safety of low dose alteplase for intravenous thrombolysis in Asian stroke patients: a meta-analysis

机译：低剂量阿替普酶对亚洲中风患者静脉溶栓治疗的疗效和安全性：一项荟萃分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Whether low dose alteplase is comparable to standard dose in efficacy and safety for intravenous thrombolysis (IVT) in Asian stroke patients remains unverified. PubMed, EMBASE, and Cochrane Library Database from the beginning to June 30, 2017 were searched. IVT efficacy was measured by favorable outcome (modified Rankin Scale scores of 0–1) at 3 months, and safety measured by mortality within 3 months and symptomatic intracerebral hemorrhage (SICH). Pooled estimates were conducted using fixed- or random-effects model depending on heterogeneity. For SICH, studies were pooled separately according to different definitions. Twelve studies involving 7,905 participants were included. No association was found between alteplase dose and favorable outcome (OR?=?0.94, 95% CI 0.78–1.14, P?=?0.5; heterogeneity: P hetero =?0.01, I2?=?57.3%) and mortality (OR?=?0.87, 95% CI 0.74–1.02, P?=?0.08; P hetero =?0.83, I2?=?0) using random- and fixed-effects models, respectively. Low dose alteplase was associated with lower SICH as defined by the National Institute of Neurological Disorders and Stroke study (OR?=?0.79, 95% CI 0.64–0.99, P?=?0.04; P hetero =?0.57, I2?=?0) using fixed-effects model. Subgroup and sensitivity analysis could change the results significantly. Current limited evidence was insufficient to support the speculation that low dose alteplase was comparable to standard dose in thrombolytic efficacy and safety in Asian stroke patients.
机译：在亚洲卒中患者中，低剂量阿替普酶在静脉溶栓治疗（IVT）的疗效和安全性方面是否可与标准剂量相媲美。搜索从2017年6月30日开始到PubMed，EMBASE和Cochrane图书馆数据库。 IVT疗效通过3个月时的有利转归（改良的Rankin量表评分为0-1）来衡量，安全性通过3个月内的死亡率和有症状的脑出血（SICH）来衡量。根据异质性，使用固定或随机效应模型进行汇总估计。对于SICH，根据不同的定义分别汇总研究。包括12项研究，涉及7,905名参与者。阿替普酶的剂量与良好的预后（OR = 0.94，95％CI 0.78-1.14，P = 0.5）之间没有相关性;异质性：P hetero = 0.01，I2 = 57.3％）和死亡率（OR = 0.93）有关。分别使用随机效应模型和固定效应模型得出== 0.87，95％CI 0.74-1.02，P == 0.08; P异质== 0.83，I2 == 0。根据国家神经疾病和中风研究所的研究，低剂量阿替普酶与较低的SICH相关（OR = 0.79，95％CI 0.64-0.99，P = 0.04; P异质= 0.57，I2 =？ 0）使用固定效果模型。亚组和敏感性分析可能会大大改变结果。目前有限的证据不足以支持低剂量阿替普酶在亚洲卒中患者的溶栓疗效和安全性方面与标准剂量相当的推测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号